Condensed Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities
Net loss	$ (4,088,134)	$ (2,827,588)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	151,493	119,517
Accretion of discount on NuvoGen obligation	126,566	47,500
Bad debt recovery, net	(16,146)
Provision for excess inventory	21,926
Amortization of term loan deferred financing costs	3,508
Amortization of discount on term loan	36,520
Amortization of final payment premium on term loan	24,237
Amortization of discount on convertible notes	32,006
Share-based compensation	76,548	42,417
Change in redeemable convertible preferred stock warrant liability	(388,960)
Amortization of convertible notes financing costs	15,107
Gain/Loss on disposal of assets	49,341
Changes in operating assets and liabilities:
Accounts receivable	(35,014)	(117,818)
Inventory	(431,598)	(106,524)
Prepaid expenses and other	(10,114)	(96,165)
Accounts payable	(69,456)	(223,288)
Accrued liabilities	83,393	(445,476)
Accrued interest	13,151
Deferred revenue	(9,233)	(64,548)
Other long term liabilities		(112,500)
Net cash used in operating activities	(4,414,859)	(3,784,473)
Investing activities
Purchase of property and equipment	(343,703)	(126,880)
Net cash used in investing activities	(343,703)	(126,880)
Financing activities
Proceeds from exercise of stock options	4,972
Draws on line of credit		750,000
Proceeds from exercise of E warrants	7,196
Deferred offering costs	(219,908)
Deferred convertible note financing costs	(75,535)
Payments on equipment lease	(7,311)
Proceeds from convertible notes	3,000,000
Net cash provided by financing activities	2,709,414	8,165,552
Increase (decrease) in cash and cash equivalents	(2,049,148)	4,254,199
Cash and cash equivalents at beginning of year	3,613,392	1,815,288
Cash and cash equivalents at end of period	1,564,244	6,069,487
Noncash investing and financing activities
Accretion of preferred stock issuance costs	24,077	22,481
Accretion of Series E warrant discount	87,470	51,377
Accretion of Series D and E redeemable convertible preferred stock dividends	798,582	740,637
Accrual of deferred offering and finance costs	96,598
Allocation of Series E warrant convertible notes debt discount	741,828
Supplemental cash flow information
Cash paid for interest	233,750	2,733
Series E Warrants
Noncash investing and financing activities
Exercise of Series E warrants	4,116
Accretion of Series E warrant discount	87,470	51,377
Series E Redeemable Convertible Preferred Stock
Financing activities
Proceeds from sale of preferred stock, net of issuance costs		$ 7,415,552